Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Neurology

Building Your Specialist Care Team

At a Glance

Managing Niemann-Pick Disease Type C requires a multidisciplinary team led by a metabolic geneticist or neurologist, alongside specialists for organ, swallowing, movement, and vision care. Proactive monitoring and bringing genetic reports and symptom videos to appointments are crucial for optimal care.

Managing Niemann-Pick Disease Type C (NPC) is a marathon that requires a specialized “support crew.” Because the disease is so rare and affects many different systems—from the brain to the liver—no single doctor can handle it alone [1][2]. Building a multidisciplinary team ensures that every symptom is monitored by an expert in that specific field [3].

Your Core Care Team

A well-rounded team typically includes these key specialists:

  • The “Quarterback” (Metabolic Geneticist or Neurologist): This doctor usually leads the team, coordinates medication therapies, and tracks neurological progression [1].
  • The Organ Specialist (Gastroenterologist or Hepatologist): Since NPC causes fat buildup in the liver and spleen, this specialist monitors organ size and function [4].
  • The Swallow Expert (Speech-Language Pathologist): Swallowing issues (dysphagia) can be dangerous if they lead to food entering the lungs. Regular swallow studies are essential for safety [5].
  • The Movement Specialist (Physical & Occupational Therapist): These experts help manage balance (ataxia) and fine motor skills, which are critical for maintaining independence [5].
  • The Eye Specialist (Neuro-Ophthalmologist): They specifically monitor vertical eye movements (VSGP), which is one of the most reliable ways to track how the disease is moving [6][7].

Preparing for Your First Appointment

Specialists in rare diseases often have long wait times. To make the most of your first visit, you should arrive with specific “physical artifacts” [1]:

  1. The Genetic Blueprint: Bring the full, printed report of your NPC1 or NPC2 genetic testing [2].
  2. Biomarker Results: Have copies of your latest blood tests for oxysterols (C-triol) or Lyso-SM-509 [8].
  3. Video Clips: It is incredibly helpful to show—not just tell—your doctor about symptoms. Use your phone to capture 30-second clips of:
    • Gelastic Cataplexy: A “head drop” or knee buckle triggered by laughter [9].
    • Eye Movements: The person trying to look quickly up and down.
    • Gait: A clip of the person walking down a hallway or stairs.

Vetting a Specialist

Not every neurologist or geneticist is an expert in NPC. Use these questions to evaluate their experience:

  • “How many active NPC patients do you manage, and how often do you see them?”
  • “Do you have experience prescribing miglustat alongside newer treatments like Miplyffa and Aqneursa?” [10]
  • “Which clinical severity scale do you use to measure progression—the NPCCSS or the SARA scale?” [11][12]
  • “Are you connected with national or international NPC registries for the latest research and clinical trial information?” [1]

The Proactive Approach

Current guidelines emphasize proactive surveillance. This means your team shouldn’t just react to new symptoms, but should perform regular tests—like annual swallow studies and eye exams—to catch changes before they become problematic [1][11]. Shared-care models, where a central NPC expert works with your local pediatrician or family doctor, are often the best way to balance top-tier expertise with day-to-day care [13].

Common questions in this guide

What doctors are needed for a Niemann-Pick Type C care team?
A well-rounded care team for NPC usually includes a metabolic geneticist or neurologist to lead care, a gastroenterologist to monitor organ health, a speech-language pathologist for swallowing, and a neuro-ophthalmologist for eye symptoms.
How should I prepare for my first appointment with an NPC specialist?
Bring printed copies of your genetic testing and biomarker blood tests, such as oxysterols. It is also highly recommended to bring short video clips on your phone demonstrating specific symptoms like gait issues, eye movements, or gelastic cataplexy.
How do doctors track the progression of Niemann-Pick Type C?
Specialists often use standardized measurements like the NPC Clinical Severity Scale (NPCCSS) or the SARA scale to monitor neurological changes over time. Routine swallow studies and eye exams are also used for proactive tracking.
What is an emergency letter for NPC?
An emergency letter is a document created by your specialist team to present to local hospitals during acute illnesses. It explains the unique risks and specific medical protocols required for someone living with Niemann-Pick Type C.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with Niemann-Pick Type C (not just Type A or B) are currently in your care?
  2. 2.Do you have a preferred protocol for coordinating with my other specialists, like my speech therapist or hepatologist?
  3. 3.How do you use the NPC Clinical Severity Scale (NPCCSS) to track my (or my child's) progression?
  4. 4.Are you familiar with the prescribing requirements for the newer targeted medications, Miplyffa and Aqneursa?
  5. 5.Can you help us create an 'emergency letter' for local hospitals to explain NPC's unique risks during an illness?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    An Australian standard of care for Niemann-Pick disease type C.

    Tchan M, Smith N, Peters H, et al.

    Internal medicine journal 2026; (56(5)):832-848 doi:10.1111/imj.70370.

    PMID: 41824299
  2. 2

    The Spectrum of Niemann-Pick Type C Disease in Greece.

    Mavridou I, Dimitriou E, Vanier MT, et al.

    JIMD reports 2017; (36()):41-48 doi:10.1007/8904_2016_41.

    PMID: 28105569
  3. 3

    Niemann-Pick type C: focus on the adolescent/adult onset form.

    Di Lazzaro V, Marano M, Florio L, De Santis S

    The International journal of neuroscience 2016; (126(11)):963-71 doi:10.3109/00207454.2016.1161623.

    PMID: 26998855
  4. 4

    Case Report: Ursodeoxycholic acid treatment in Niemann-Pick disease type C; clinical experience in four cases.

    Evans WRH, Nicoli ER, Wang RY, et al.

    Wellcome open research 2017; (2()):75 doi:10.12688/wellcomeopenres.11854.1.

    PMID: 29119141
  5. 5

    Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life.

    Wu M, Ceponiene R, Bayram E, Litvan I

    Movement disorders clinical practice 2020; (7(8)):961-964 doi:10.1002/mdc3.13085.

    PMID: 33163568
  6. 6

    A cross-sectional, prospective ocular motor study in 72 patients with Niemann-Pick disease type C.

    Bremova-Ertl T, Abel L, Walterfang M, et al.

    European journal of neurology 2021; (28(9)):3040-3050 doi:10.1111/ene.14955.

    PMID: 34096670
  7. 7

    Vertical saccadic palsy and foveal retinal thinning in Niemann-Pick disease type C.

    Hopf S, Hennermann JB, Schuster AK, et al.

    PloS one 2021; (16(6)):e0252825 doi:10.1371/journal.pone.0252825.

    PMID: 34086834
  8. 8

    A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease.

    Giese AK, Mascher H, Grittner U, et al.

    Orphanet journal of rare diseases 2015; (10()):78 doi:10.1186/s13023-015-0274-1.

    PMID: 26082315
  9. 9

    A Suspicion Index to aid screening of early-onset Niemann-Pick disease Type C (NP-C).

    Pineda M, Mengel E, Jahnová H, et al.

    BMC pediatrics 2016; (16()):107 doi:10.1186/s12887-016-0641-7.

    PMID: 27449637
  10. 10

    Arimoclomol: First Approval.

    Keam SJ

    Drugs 2025; (85(1)):111-116 doi:10.1007/s40265-024-02129-x.

    PMID: 39715913
  11. 11

    Consistently High Agreement Between Independent Raters of Niemann-Pick Type C1 Clinical Severity Scale in Phase 2/3 Trial.

    Farhat N, Bailey L, Friedmann K, et al.

    Pediatric neurology 2022; (127()):32-38 doi:10.1016/j.pediatrneurol.2021.11.009.

    PMID: 34952292
  12. 12

    Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C.

    Bremova-Ertl T, Ramaswami U, Brands M, et al.

    The New England journal of medicine 2024; (390(5)):421-431 doi:10.1056/NEJMoa2310151.

    PMID: 38294974
  13. 13

    Consensus clinical management guidelines for Niemann-Pick disease type C.

    Geberhiwot T, Moro A, Dardis A, et al.

    Orphanet journal of rare diseases 2018; (13(1)):50 doi:10.1186/s13023-018-0785-7.

    PMID: 29625568

This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider or metabolic specialist about building a care team for Niemann-Pick Disease Type C.

Get notified when new evidence is published on Niemann-Pick disease type C.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.